Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | PPM1B | O75688 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | TFPI2 | P48307 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 2/20 | 1.00 |
| ▸ | PPP5C | P53041 | 2/20 | 1.00 |
| ▸ | PPP1CA | P62136 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demethyl-Cantharidin SCHEMBL177729 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Norcantharidin SCHEMBL29380910 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL9675442 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL3187662 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL3195020 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL19318920 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL9906842 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL16938608 | 0.84 | KDM4E (0.71) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL17695028 | 0.84 | KDM4E (0.71) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL12599313 | 0.74 | KDM4E (0.57) | TP53LMNAPPM1BSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | G1 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-1458723-A4 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | EGFR, CDK4, CDK6 | TP53 89/4885LMNA 4227/4885PPM1B 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.